TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this single- arm, open-lable, dose escalation + dose expansion study is to
evalulate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in
Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI
treatments.